RT info:eu-repo/semantics/article
T1 Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin
A1 Pérez Castrillon, José Luis
A1 Zarrabeitia Cimiano, María Teresa
A1 Abad Manteca, Laura
A1 Vega, Gemma
A1 Ruiz Mambrilla, Marta María
A1 González Sagrado, Manuel
A1 Dueñas Laita, Antonio
A1 Riancho Moral, José Antonio
K1 Osteoporosis
AB Although their primary therapeutic indicationsare different, aminobisphosphonates and statins targetenzymes in the mevalonate pathway, which is critical forbone homeostasis. Previous studies have shown that somepolymorphisms of the gene encoding farnesyl diphosphatesynthase (FDPS), the main target of aminobisphosphonates,modulate the response to these drugs. In this study,we explored whether those single nucleotide polymorphisms(SNPs) also influence the changes in bone mineraldensity (BMD) following therapy with statins. Sixty-sixpatients with coronary heart disease were studied at baselineand after 1-year therapy with atorvastatin. BMDwas measured by DXA. Three SNPs of the FDPS gene(rs2297480, rs11264359 and rs17367421) were analyzed by using Taqman assays. The results showed that there wasno association between the SNPs and basal BMD. However,rs2297480 and rs11264359 alleles, which are in linkagedisequilibrium, were associated with changes in hipBMD following atorvastatin therapy. Thus, patients withAA genotype at the rs2297480 locus had a 0.8 ± 0.8 %increase in BMD at the femoral neck, whereas in patientswith AC/CC genotypes, BMD showed a 2.3 ± 0.8 %decrease (p = 0.02). Similar results were obtained regardingchanges of BMD at the femoral trochanter and whenalleles at the rs11264359 locus were analyzed. However,there was no association between BMD and rs17367421alleles. In conclusion, these results suggest that polymorphismsof the FDPS gene may influence the bone responseto various drugs targeting the mevalonate pathway, includingnot only aminobisphosphonates but also statins.
PB Springer-Verlag Berlin Heidelberg
SN 0172-8172
YR 2013
FD 2013
LK http://uvadoc.uva.es/handle/10324/5940
UL http://uvadoc.uva.es/handle/10324/5940
LA eng
NO Rheumatology International, 2013, p. 1-5
NO Producción Científica
DS UVaDOC
RD 04-dic-2024